safety · applied
Reference snapshot
This snapshot describes the state of the editorial record, not a diagnosis or a recommendation to intervene.
Claim ledger
These are declared editorial claim-to-source mappings. A mapping does not establish independent verification of the claim or its support. Citation controls open the corresponding source record.
Signal
Product identity, purity, dose, interactions, and regulatory status are prerequisites for interpreting any proposed supplement mechanism.
Boundary
Short-term target engagement or tolerability in a defined study does not resolve long-term safety, product equivalence, or meaningful clinical outcomes.
Not established
A plausible pathway, online certificate, or unapproved product claim does not establish that a commercial formulation is safe or effective for personal use.
Mechanism map (working model)
A simplified causal map for orientation; it is not a diagnosis or a deterministic prediction.
Input or intervention
Supplement Quality and Product Verification
Biological pathway
safety pathway shaped by dose, context, and individual response
Measurable signal
Product identity, purity, contamination, labeling, interactions, and regulatory status often matter more than a supplement's proposed mechanism.
Boundary
Contamination, adulteration, interactions, organ toxicity, and delayed medical care.
Research appraisal checklist
Evidence to prioritize
Human comparative studies, validated measurement, realistic adherence, dose or context reporting, and evidence that the effect transfers beyond the training setting.
Outcome anchor
Anchor the claim to a meaningful functional or clinical outcome rather than a single dashboard metric or biomarker.
Main uncertainty
The main uncertainty is whether the observed signal is causal, durable, and relevant outside the exact study context.
What would change the conclusion
Upgrade confidence only when independent studies reproduce the result and make harms, adherence, and durability visible.
Minimum diligence questions
- Are the intervention, dose or exposure, comparator, population, and measurement conditions clearly defined?
- Do the outcomes matter outside the experiment, and are missing data, adverse events, and conflicts visible?
- Can the result be reproduced independently, and does it justify the level of risk being discussed?
Application and translation pathway
Current application boundary
Supplement Quality and Product Verification is currently best understood as a applied safety domain; practical use should stay within the evidence and safety boundary described in this dossier.
Research and applied uses
- Measurement and hypothesis testing in safety
- Protocol design with defined outcomes and context
- Low-risk applied experimentation with reversible changes
A staged map for separating an interesting mechanism from a reproducible, useful, and responsibly deployable application.
Question
Define the population, intervention, comparator, and outcome before interpreting a signal.
Signal
Check measurement validity, adherence, confounding, and whether the result repeats.
Function
Ask whether the change improves meaningful daily function or clinical outcomes.
Boundary
Preserve normal functioning and stop when symptoms or risk increase.
Research and clinical readout
Research status
Supplement evidence often hinges on identity, dose, purity, interactions, and regulatory status before the proposed mechanism can be meaningfully evaluated.
Signal confidence
Grade B (High for the importance of product verification and medication review; variable for efficacy and long-term safety of specific compounds.)
Key question
Does a verified product improve a prespecified outcome at a dose and duration with an acceptable safety margin?
Clinical perspective
Use food-first foundations, review medications and conditions, and choose products with credible quality controls.
Clinical uncertainty
Whether selected supplements are worthwhile after correcting a measured deficiency or specific clinical indication.
Community patterns
Users trust transparent labels and batch testing more than elaborate mechanism narratives.
Common community failure mode
Stacking many products makes attribution and interaction monitoring impossible.
Where this is heading
Better lot-level testing, adverse-event data, and regulatory clarity may move quality from a marketing claim toward a verifiable property.
What to track next
Product identity, purity, contamination, labeling, interactions, and regulatory status often matter more than a supplement's proposed mechanism.
Protocol and safety scaffold
Risk gate: Start with low-risk foundations and preserve normal functioning while testing one variable.
Baseline first
- Define one meaningful outcome and a comparison window before changing the protocol.
- Record relevant symptoms, sleep, workload, medications, and confounders at baseline.
Implementation pattern
- Change one variable at a time and use the smallest meaningful intervention.
- Predefine review, washout, and escalation criteria before looking at results.
Monitor
- Track the target outcome alongside symptoms, function, and adherence.
- Check data quality and context before treating a change as a signal.
Pause or stop rules
- Pause for new or worsening symptoms, reduced normal function, or a meaningful safety concern.
- Pause signal: Proprietary blends, disease claims, and injectable products sold as casual wellness tools.
- Pause signal: No batch information, third-party verification, or adverse-event pathway.
Clinician gate
Use clinician review for persistent symptoms, medication changes, abnormal results, pregnancy, or a diagnosed medical condition.
Glossary connections
Controversies to monitor
Controversies
- Unapproved products sold through medical-sounding wellness channels.
- Short-term biomarker movement being used to justify indefinite dosing.
Core reference classes
Research classes
- FDA safety communications on unapproved products
- Randomized NAD and investigational peptide studies
Evidence timeline
Linked records are ordered by publication year. A newer record is not automatically stronger; design, population, and endpoint still determine weight.
Collagen Supplementation for Skin and Musculoskeletal Health
PubMed - Umbrella review of meta-analyses
A 2026 umbrella review integrates meta-analyses of collagen supplementation for skin, musculoskeletal, and osteoarthritis outcomes while examining heterogeneity and evidence certainty.
View source recordCompounding and the FDA: Questions and Answers
U.S. Food and Drug Administration - Regulatory and safety guidance
FDA explains why compounded drugs may be useful for specific patient needs but are not FDA-approved and are not verified by FDA for safety, effectiveness, or quality before marketing.
View source recordUnapproved Drugs
U.S. Food and Drug Administration - Regulatory safety information
FDA warns that unapproved prescription drugs have not been reviewed for safety, effectiveness, or consistent quality, and that lawful access in limited circumstances does not equal general approval.
View source recordFDALabel: Full-Text Search of Drug Product Labeling
U.S. Food and Drug Administration - Regulatory information resource
FDALabel provides searchable FDA drug-label information that can help researchers and clinicians verify approved indications, warnings, and labeling context before discussing repurposing claims.
View source recordHow Gene Therapy Can Cure or Treat Diseases
U.S. Food and Drug Administration - Regulatory explainer
FDA’s public explainer distinguishes therapeutic gene-editing pathways from consumer experimentation and emphasizes clinical testing for safety and effectiveness.
View source recordComparing NAD+ Boosters in Healthy Adults
Nature Metabolism / PubMed - Randomized open-label placebo-controlled study
A randomized study in 65 healthy participants compared nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide over 14 days and reported increased circulating NAD+ with NR and NMN; functional and long-term outcomes remain separate questions.
View source recordFirst-in-Human Topical TCP-25 Peptide Safety Study
Clinical and Translational Science / PubMed - First-in-human randomized placebo-controlled phase 1 study
A first-in-human randomized study evaluated topical TCP-25 gel in healthy volunteers with epidermal suction-blister wounds and found no serious or significant treatment-related safety signal in the short study; therapeutic efficacy remains investigational.
View source recordDietary Supplements and Male Infertility Outcomes
Nutrients / PubMed - Systematic review and meta-analysis
A 2025 meta-analysis found no convincing supplement effect on pregnancy or live birth and generally low or very low certainty for sperm-parameter findings.
View source recordTretinoin for Photodamaged Facial Skin
Dermatology Practical & Conceptual / PubMed - Systematic review and meta-analysis of randomized trials
A 2025 meta-analysis evaluates topical tretinoin for photodamaged facial skin and helps separate a prescription retinoid with defined endpoints from broad cosmetic supplement or peptide claims.
View source recordMinoxidil and 5-Alpha Reductase Inhibitors for Male Pattern Hair Loss
Journal of Cosmetic Dermatology / PubMed - Network meta-analysis
A 2025 network meta-analysis compares minoxidil, finasteride, and dutasteride routes and doses for male androgenetic alopecia while reinforcing that efficacy, safety, and route cannot be separated.
View source recordMultivitamin and Mineral Use: A Rapid Review of Meta-Analyses on Health Outcomes
Ageing Research Reviews / PubMed - Rapid review of meta-analyses
A 2025 rapid review found outcome-specific signals for multivitamin and mineral use, including selected cognition and blood-pressure findings, but no established all-cause mortality or universal longevity benefit.
View source recordBeyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment
Peptide Science / PubMed - Safety and regulatory review
A 2025 review emphasizes that peptide immunogenicity can arise from the molecule, impurities, or formulation and requires structured assessment during development and authorization.
View source recordWarnings on Peptides, Stem Cells, and Unapproved Cellular Products
U.S. Food and Drug Administration - Regulatory warning
Official regulator warnings provide a high-risk check for advertised products whose purity, legality, or clinical claims may not be reliable.
View source recordAmycretin: GLP-1 and Amylin Receptor Agonism
The Lancet / PubMed - Randomized placebo-controlled phase 1b/2a clinical trial
A phase 1b/2a randomized study evaluated investigational subcutaneous amycretin for safety, pharmacokinetics, and body-weight effects in adults with overweight or obesity; gastrointestinal adverse events and substantial discontinuation context are important to interpretation.
View source recordCreatine Supplementation and Cognitive Function in Adults
Frontiers in Nutrition / PubMed - Systematic review and meta-analysis of randomized trials
A systematic review and meta-analysis of randomized trials found domain-specific signals for memory, attention time, and processing speed, while overall cognition and executive-function findings remained less certain and population effects varied.
View source recordVitamin B6: Health Professional Fact Sheet
NIH Office of Dietary Supplements - Government clinical nutrition reference
Excess supplemental B6 can cause sensory neuropathy; water solubility is not a guarantee of safety.
View source recordSupplemental Vitamin D and Incident Fractures in Midlife and Older Adults
New England Journal of Medicine - Randomized placebo-controlled ancillary trial
VITAL tested fracture prevention in adults not selected for deficiency or osteoporosis.
View source recordWhat You Need to Know About Products Containing Cannabis or Cannabis-Derived Compounds, Including CBD
U.S. Food and Drug Administration - Regulatory consumer guidance
FDA describes limited consumer safety data for CBD, potential liver injury and drug interactions, sedation with alcohol or other CNS depressants, and the difference between an approved CBD medicine and unapproved consumer products.
View source recordPlant-Derived Nootropics and Human Cognition
Critical Reviews in Food Science and Nutrition / PubMed - Systematic review
A systematic review mapped human evidence for plant-derived nootropics and described both reported cognitive signals and substantial inconsistency, supporting a substance-specific rather than category-wide interpretation.
View source recordFDA Warning on Unapproved Heavy-Metal Chelation Supplements
U.S. Food and Drug Administration - Regulatory warning
FDA warned against products marketed as dietary supplements for heavy-metal toxicity or chelation and emphasized that prescription chelators are approved only for specific indications.
View source recordTopic assessment
These questions test evidence interpretation and safety boundaries, not personal medical decisions.
1. What is the most defensible first question when evaluating Supplement Quality and Product Verification?
Show answer and explanation
What outcome, evidence, and risk boundary are defined?
A clear outcome, evidence design, and risk boundary keep an encyclopedia claim from becoming an unsafe recommendation.
2. What would make a claim about Supplement Quality and Product Verification more trustworthy?
Show answer and explanation
Replication with appropriate controls, context, and meaningful outcomes
Reproducibility and patient-important outcomes matter more than novelty, complexity, or an isolated signal.
Editorial update history
This log records what changed in the encyclopedia record and why the update matters for interpretation.
Added a cannabinoid dossier connecting THC, CBD, prescription medicines, chronic-pain evidence, anxiety research, cognitive and impairment effects, dependence, product quality, interactions, and regulatory boundaries.
Related record update: What You Need to Know About Products Containing Cannabis or Cannabis-Derived Compounds, Including CBD
A-Z topic scaffolding, safety framing, learning paths, and linked evidence architecture established for the living encyclopedia.
Added current records spanning real-world digital cohorts, multi-omics, serum proteomics, sweat biosensing, peptides, aging clocks, kinase signaling, endocrine research, personalized nutrition, microbiome response, neurotechnology, and caloric restriction.
Related record update: Amycretin: GLP-1 and Amylin Receptor Agonism; First-in-Human Topical TCP-25 Peptide Safety Study
Added encyclopedia coverage for breathwork, creatine cognition, intermittent hypoxia, ketogenic metabolism, mindfulness and interoception, nootropics, photobiomodulation, and psychedelic-assisted therapy, with topic-specific safety framing and current evidence links.
Related record update: Creatine Supplementation and Cognitive Function in Adults; Plant-Derived Nootropics and Human Cognition
Added indication-specific testosterone and male-fertility coverage alongside N-of-1 trial design and placebo, expectancy, and nocebo literacy, with explicit clinical gates and causal-inference boundaries.
Related record update: Dietary Supplements and Male Infertility Outcomes
Added female fertility and ovarian-reserve interpretation, menstrual-cycle and energy-availability boundaries, oral microbiome and periodontal-health coverage, and skin photoaging and photoprotection evidence with device-specific and clinical safeguards.
Related record update: Tretinoin for Photodamaged Facial Skin
Added high-stakes multi-cancer detection and liquid-biopsy framing, immunosenescence and vaccine-response research, joint and tendon collagen evidence, and subtype-aware hair-loss treatment coverage with clinical-utility and safety boundaries.
Related record update: Collagen Supplementation for Skin and Musculoskeletal Health; Minoxidil and 5-Alpha Reductase Inhibitors for Male Pattern Hair Loss
Added dedicated dossiers for vitamin and micronutrient repletion, peptide therapeutics and research-grade compounds, off-label medication repurposing, and compounded or online-sourced medications, with current nutrition evidence, human peptide pharmacology, FDA labeling resources, and product-quality boundaries.
Related record update: Multivitamin and Mineral Use: A Rapid Review of Meta-Analyses on Health Outcomes; Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment; Compounding and the FDA: Questions and Answers; Unapproved Drugs; FDALabel: Full-Text Search of Drug Product Labeling
Added a high-risk detoxification dossier connecting exposure source control, validated testing, CDC lead guidance, FDA chelation warnings, detox-diet evidence, sweat-excretion limits, and product-quality safeguards.
Related record update: FDA Warning on Unapproved Heavy-Metal Chelation Supplements
Linked evidence records
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
New England Journal of Medicine • Randomized placebo-controlled ancillary trial • Published: 2022-07-28 • Checked: Oct 26, 2026
VITAL tested fracture prevention in adults not selected for deficiency or osteoporosis.
How to interpret this record
Study at a glance
- Who was studied
- 25,871 adults; men ≥50 and women ≥55. Not recruited for vitamin-D deficiency, low bone mass, or osteoporosis.
- What was compared
- Vitamin D3 2,000 IU daily versus placebo within VITAL. Trial exposure, not a personal recommendation.
- What was measured
- Incident total fractures; median follow-up 5.3 years.
- Reported result
- Hazard ratio 0.98 (95% CI 0.89–1.08).
- How to read the numbers
- No demonstrated fracture reduction in this population; the interval includes no difference.
- Where this result stops
- Not a trial of treating diagnosed deficiency. Does not settle every nutrient, life stage, or clinical indication.
- Source and version
- PMID 35939577, indexed abstract; checked October 26, 2026.
What it supports
A randomized test of fracture prevention in this population.
Major limitations
Enrollment did not target deficiency or osteoporosis.
What it does not establish
That treating diagnosed deficiency is ineffective.
Vitamin B6: Health Professional Fact Sheet
NIH Office of Dietary Supplements • Government clinical nutrition reference • Published: 2023-06-16 • Checked: Oct 26, 2026
Excess supplemental B6 can cause sensory neuropathy; water solubility is not a guarantee of safety.
How to interpret this record
What it supports
Recognition of excess-intake neurological risk.
Major limitations
Individual exposure and context require clinical review.
What it does not establish
That a water-soluble vitamin is harmless at any intake.
What You Need to Know About Products Containing Cannabis or Cannabis-Derived Compounds, Including CBD
U.S. Food and Drug Administration • Regulatory consumer guidance • Published: 2022 • Checked: Aug 17, 2026
FDA describes limited consumer safety data for CBD, potential liver injury and drug interactions, sedation with alcohol or other CNS depressants, and the difference between an approved CBD medicine and unapproved consumer products.
How to interpret this record
What it supports
FDA identifies real safety and regulatory concerns for consumer CBD, including possible liver injury, drug interactions, sedation, and unknown product quality.
Major limitations
The guidance is not a randomized efficacy review and does not characterize every product, formulation, dose, or jurisdiction.
What it does not establish
A hemp or CBD label does not establish purity, therapeutic efficacy, harmlessness, or equivalence to an approved CBD medicine.
Dietary Supplements and Male Infertility Outcomes
Nutrients / PubMed • Systematic review and meta-analysis • Published: 2025 • Checked: Aug 17, 2026
A 2025 meta-analysis found no convincing supplement effect on pregnancy or live birth and generally low or very low certainty for sperm-parameter findings.
How to interpret this record
What it supports
The meta-analysis found no convincing effect of dietary supplements on pregnancy or live birth and generally low or very low certainty for sperm parameters.
Major limitations
Supplement formulations, populations, durations, and risk of bias varied; individual sperm-parameter signals do not all translate to conception.
What it does not establish
A supplement stack or improved semen value is not proof of increased fertility, pregnancy, or live birth.
Tretinoin for Photodamaged Facial Skin
Dermatology Practical & Conceptual / PubMed • Systematic review and meta-analysis of randomized trials • Published: 2025 • Checked: Aug 17, 2026
A 2025 meta-analysis evaluates topical tretinoin for photodamaged facial skin and helps separate a prescription retinoid with defined endpoints from broad cosmetic supplement or peptide claims.
How to interpret this record
What it supports
Randomized trials support topical tretinoin for selected photodamage and wrinkle outcomes when used as a defined dermatologic treatment.
Major limitations
Irritation, adherence, formulation, concentration, treatment duration, and participant characteristics influence observed benefit and tolerability.
What it does not establish
Tretinoin is not a universal anti-aging supplement, and a prescription retinoid should not be self-started without attention to contraindications and clinical context.
Collagen Supplementation for Skin and Musculoskeletal Health
PubMed • Umbrella review of meta-analyses • Published: 2026 • Checked: Aug 17, 2026
A 2026 umbrella review integrates meta-analyses of collagen supplementation for skin, musculoskeletal, and osteoarthritis outcomes while examining heterogeneity and evidence certainty.
How to interpret this record
What it supports
Collagen supplementation has been studied across skin, musculoskeletal, and osteoarthritis outcomes, with favorable signals that vary by endpoint and formulation.
Major limitations
Underlying reviews differ in populations, products, training, outcomes, risk of bias, and evidence certainty; supplement quality and clinical magnitude remain important.
What it does not establish
A collagen product is not established as a universal joint repair, cartilage-regeneration, injury-prevention, or anti-aging intervention.
Minoxidil and 5-Alpha Reductase Inhibitors for Male Pattern Hair Loss
Journal of Cosmetic Dermatology / PubMed • Network meta-analysis • Published: 2025 • Checked: Aug 17, 2026
A 2025 network meta-analysis compares minoxidil, finasteride, and dutasteride routes and doses for male androgenetic alopecia while reinforcing that efficacy, safety, and route cannot be separated.
How to interpret this record
What it supports
Comparative evidence can help rank minoxidil and 5-alpha-reductase inhibitor routes and doses for male androgenetic alopecia.
Major limitations
Network comparisons depend on indirect evidence, treatment duration, adherence, baseline severity, and route-specific adverse effects.
What it does not establish
A ranking does not establish that a drug is appropriate, safe in pregnancy, or suitable for a person without a confirmed alopecia subtype.
Multivitamin and Mineral Use: A Rapid Review of Meta-Analyses on Health Outcomes
Ageing Research Reviews / PubMed • Rapid review of meta-analyses • Published: 2025 • Checked: Aug 17, 2026
A 2025 rapid review found outcome-specific signals for multivitamin and mineral use, including selected cognition and blood-pressure findings, but no established all-cause mortality or universal longevity benefit.
How to interpret this record
What it supports
Multivitamin and mineral interventions show outcome-specific signals in selected populations, including some cognition and blood-pressure outcomes.
Major limitations
The review combines different formulations, populations, doses, durations, and endpoints; pooled signals do not establish a universal healthspan or longevity effect.
What it does not establish
Taking a multivitamin does not prove longer life, broad disease prevention, or a need for high-dose stacking when nutritional adequacy is already present.
Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment
Peptide Science / PubMed • Safety and regulatory review • Published: 2025 • Checked: Aug 17, 2026
A 2025 review emphasizes that peptide immunogenicity can arise from the molecule, impurities, or formulation and requires structured assessment during development and authorization.
How to interpret this record
What it supports
Peptide development requires explicit assessment of immunogenicity, impurities, formulation, and assay quality in addition to efficacy.
Major limitations
This is a safety and regulatory review, not evidence that any particular research peptide is effective or safe for self-use.
What it does not establish
A peptide's natural origin, short sequence, or early pharmacology does not guarantee low immunogenicity, purity, sterility, or therapeutic value.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration • Regulatory and safety guidance • Published: 2026 • Checked: Aug 17, 2026
FDA explains why compounded drugs may be useful for specific patient needs but are not FDA-approved and are not verified by FDA for safety, effectiveness, or quality before marketing.
How to interpret this record
What it supports
Compounding can address a specific patient need when an approved product is unsuitable, within applicable pharmacy and legal requirements.
Major limitations
Compounded drugs are not FDA-approved and quality, oversight, formulation, and accountability depend on the product and compounder.
What it does not establish
A compounded product is not automatically equivalent to an approved product, and a certificate or online reputation does not prove clinical suitability.
Unapproved Drugs
U.S. Food and Drug Administration • Regulatory safety information • Published: 2026 • Checked: Aug 17, 2026
FDA warns that unapproved prescription drugs have not been reviewed for safety, effectiveness, or consistent quality, and that lawful access in limited circumstances does not equal general approval.
How to interpret this record
What it supports
Unapproved-drug status is a meaningful safety and quality boundary because FDA has not reviewed the product for its intended use.
Major limitations
Limited lawful access or professional reliance in specific circumstances does not create general approval or establish benefit.
What it does not establish
‘Research use only,’ availability online, or a reported personal success does not establish identity, sterility, potency, effectiveness, or safety.
FDALabel: Full-Text Search of Drug Product Labeling
U.S. Food and Drug Administration • Regulatory information resource • Published: 2026 • Checked: Aug 17, 2026
FDALabel provides searchable FDA drug-label information that can help researchers and clinicians verify approved indications, warnings, and labeling context before discussing repurposing claims.
How to interpret this record
What it supports
Searchable official labeling can anchor discussions of approved indications, warnings, routes, and monitoring requirements.
Major limitations
Label verification is a starting point and does not replace clinical judgment, current contraindication review, or evidence appraisal for a new use.
What it does not establish
Finding a drug in an FDA label database does not mean the proposed off-label protocol is approved or appropriate for an individual.
How Gene Therapy Can Cure or Treat Diseases
U.S. Food and Drug Administration • Regulatory explainer • Published: 2026 • Checked: Aug 17, 2026
FDA’s public explainer distinguishes therapeutic gene-editing pathways from consumer experimentation and emphasizes clinical testing for safety and effectiveness.
How to interpret this record
What it supports
The distinction between regulated therapeutic gene therapy and unapproved consumer experimentation.
Major limitations
This is an educational regulatory source, not a comparative clinical trial.
What it does not establish
Approved or investigational therapeutic pathways do not make self-directed gene editing acceptable.
Warnings on Peptides, Stem Cells, and Unapproved Cellular Products
U.S. Food and Drug Administration • Regulatory warning • Published: 2025 • Checked: Aug 17, 2026
Official regulator warnings provide a high-risk check for advertised products whose purity, legality, or clinical claims may not be reliable.
How to interpret this record
What it supports
A high-risk screening signal for product claims, sourcing, labeling, and regulatory status.
Major limitations
A warning about one seller or product does not characterize every product in a category.
What it does not establish
Marketing claims and product availability are not evidence of purity, safety, or efficacy.
Comparing NAD+ Boosters in Healthy Adults
Nature Metabolism / PubMed • Randomized open-label placebo-controlled study • Published: 2026 • Checked: Aug 17, 2026
A randomized study in 65 healthy participants compared nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide over 14 days and reported increased circulating NAD+ with NR and NMN; functional and long-term outcomes remain separate questions.
How to interpret this record
What it supports
In healthy adults, short-term NR and NMN supplementation increased circulating NAD+ concentrations relative to nicotinamide or placebo conditions in the study design.
Major limitations
The intervention was brief and focused on target engagement; functional outcomes, long-term safety, and disease prevention were not established by this comparison.
What it does not establish
Raising a circulating NAD+ measure does not prove anti-aging, performance, cognitive, or lifespan benefit.
Amycretin: GLP-1 and Amylin Receptor Agonism
The Lancet / PubMed • Randomized placebo-controlled phase 1b/2a clinical trial • Published: 2025 • Checked: Aug 17, 2026
A phase 1b/2a randomized study evaluated investigational subcutaneous amycretin for safety, pharmacokinetics, and body-weight effects in adults with overweight or obesity; gastrointestinal adverse events and substantial discontinuation context are important to interpretation.
How to interpret this record
What it supports
The phase 1b/2a trial provides early regulated-drug evidence on dose escalation, pharmacokinetics, body-weight outcomes, and adverse events for investigational amycretin.
Major limitations
This is an investigational pharmaceutical study with sponsor and trial-specific context, dose-dependent tolerability, withdrawals, and no basis for unsupervised use.
What it does not establish
A clinical-trial result does not make an unapproved peptide or receptor agonist appropriate to source, compound, or dose outside regulated care.
First-in-Human Topical TCP-25 Peptide Safety Study
Clinical and Translational Science / PubMed • First-in-human randomized placebo-controlled phase 1 study • Published: 2026 • Checked: Aug 17, 2026
A first-in-human randomized study evaluated topical TCP-25 gel in healthy volunteers with epidermal suction-blister wounds and found no serious or significant treatment-related safety signal in the short study; therapeutic efficacy remains investigational.
How to interpret this record
What it supports
The first-in-human study provides short-term topical safety, tolerability, pharmacokinetic, and exploratory wound data for TCP-25 in healthy volunteers.
Major limitations
The sample, topical route, wound model, short follow-up, and exploratory endpoints limit clinical and consumer generalization.
What it does not establish
A favorable phase 1 safety signal does not establish wound-healing efficacy, systemic safety, or use of research peptides outside a trial.
Creatine Supplementation and Cognitive Function in Adults
Frontiers in Nutrition / PubMed • Systematic review and meta-analysis of randomized trials • Published: 2024 • Checked: Aug 17, 2026
A systematic review and meta-analysis of randomized trials found domain-specific signals for memory, attention time, and processing speed, while overall cognition and executive-function findings remained less certain and population effects varied.
How to interpret this record
What it supports
A randomized-trial synthesis supports domain-specific investigation of creatine for memory, attention, and processing outcomes.
Major limitations
The included populations, cognitive tasks, durations, dietary context, and certainty vary; overall cognition and executive-function results are less settled.
What it does not establish
The evidence does not establish creatine as a universal nootropic, intelligence enhancer, or substitute for sleep and clinical care.
Plant-Derived Nootropics and Human Cognition
Critical Reviews in Food Science and Nutrition / PubMed • Systematic review • Published: 2022 • Checked: Aug 17, 2026
A systematic review mapped human evidence for plant-derived nootropics and described both reported cognitive signals and substantial inconsistency, supporting a substance-specific rather than category-wide interpretation.
How to interpret this record
What it supports
The review identifies which plant-derived cognitive-enhancement claims have been studied and where results remain inconsistent.
Major limitations
The evidence is older, products and extracts vary, trials are heterogeneous, and review-level findings do not resolve purity, interactions, or modern gray-market formulations.
What it does not establish
A plant-derived label does not establish safety, efficacy, legality, or a reason to combine multiple nootropics.
FDA Warning on Unapproved Heavy-Metal Chelation Supplements
U.S. Food and Drug Administration • Regulatory warning • Published: 2014 • Checked: Aug 17, 2026
FDA warned against products marketed as dietary supplements for heavy-metal toxicity or chelation and emphasized that prescription chelators are approved only for specific indications.
How to interpret this record
What it supports
FDA’s warning distinguishes prescription chelation for specific indications from unapproved supplements marketed with heavy-metal or detox claims.
Major limitations
A regulatory warning about particular products does not replace evaluation of a confirmed exposure or every future formulation.
What it does not establish
Listing an approved chelator ingredient on a supplement label does not establish product approval, purity, dose, or safe self-treatment.